# US 2017/0281692 A1 · Microbiota restoration therapy (mrt), compositions and methods of manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281692 A1
- Document ID: US20170281692A1
- Status: Published application
- Kind: A1
- Application number: 15/625,715
- Filed: 2017-06-16
- Published: 2017-10-05
- Earliest claimed: 2013-06-05
- Assignees: Rebiotix, Inc.
- Applicants: Rebiotix, Inc.
- Inventors: LEE A. JONES; COURTNEY R. JONES; EDWIN J. HLAVKA; RYAN D. GORDON
- Web page: https://patentgrep.com/patent/US20170281692A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A01N 1/122: Preservation or perfusion media
- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- B65B 7/02: Closing containers or receptacles deformed by, or taking-up shape, of, contents, e.g. bags, sacks
- B65B 25/00: Packaging other articles presenting special problems (bundling B65B27/00)
- C12N 1/20: Bacteria; Culture media therefor
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B65B: MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING (bundling and pressing devices for cigars A24C1/44; devices for tensioning and securing binders adapted to be supported by the article or articles to be bound B25B25/00; applying closure members to bottles, jars or similar containers B67B1/00-B67B6/00; concurrent cleaning, filling and closing of bottles B67C7/00; emptying bottles, jars, cans, casks, barrels or similar containers B67C9/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

## Claims

### Claim 1

A method for treating dysbiosis, the method comprising:
administering a microbiota restoration therapy composition to a patient with dysbiosis; and
wherein the microbiota restoration therapy composition is manufactured by:
collecting a fresh human fecal sample, and
adding a diluent to the fresh human fecal sample, the diluent including 30-90 g/L polyethylene glycol in saline.

### Claim 2 (depends on 1)

The method of claim 1, wherein administering the microbiota restoration therapy composition to the patient with dysbiosis includes administering the microbiota restoration therapy via an enema tube.

### Claim 3 (depends on 1)

The method of claim 1, wherein administering the microbiota restoration therapy composition to the patient with dysbiosis includes administering the microbiota restoration therapy composition orally.

### Claim 4 (depends on 1)

The method of claim 1, wherein the microbiota restoration therapy is characterized for genetic biodiversity prior to administering the microbiota restoration therapy.

### Claim 5 (depends on 4)

The method of claim 4, wherein the microbiotia restoration therapy composition includes bacteria from at least two orders and at least seven different families.

### Claim 6 (depends on 4)

The method of claim 4, wherein the microbiota restoration therapy composition has a Shannon Diversity Index of 0.4-2.5 when calculated at the family level,

### Claim 7 (depends on 5)

The method of claim 5, wherein in the range of 40-60% of the bacteria is from the order Bacteroidales, in the range of 30-40% of the bacteria is from the order Clostridiales, and in the range of 36-48% of the bacteria is from the family Bacteroidaceae.

### Claim 8 (depends on 1)

The method of claim 1, wherein the viability of the microbiota within the filtrate is confirmed by culturing the microbiota on a Bacteroides Bile Esculin Agar (BBE) plate, a Center for Disease Control (CDC) plate, or both.

### Claim 9 (depends on 9)

The method of claim 9, wherein the viability of the microbiota within the filtrate is confirmed on a BBE plate by a colony forming unit (CFU) count of about 30 CFU to about 300 CFU at a serial dilution of 10−5.

### Claim 10 (depends on 1)

The method of claim 1, wherein a volume of the microbiota restoration therapy composition administered is about 50 milliliters.

### Claim 11

A method for treating an imbalance of the intestinal bacterial flora, the method comprising:
administering a microbiota restoration therapy composition to a patient with imbalance of the intestinal bacterial flora;
wherein the microbiota restoration therapy composition is manufactured by:
collecting a fresh human fecal sample;
adding a diluent to the fresh human fecal sample to form a diluted sample;
wherein the diluent includes a cryoprotectant in saline;
mixing the diluted sample with a mixing apparatus; and
filtering the mixture to form a filtrate, the filtrate forming the microbiota restoration therapy composition;
wherein the microbiota restoration therapy is pre-screened for bacterial diversity and includes bacteria from six or more different taxonomic families.

### Claim 12 (depends on 11)

The method of claim 11, wherein the diluent includes 30-90 g/L polyethylene glycol in saline.

### Claim 13 (depends on 11)

The method of claim 11, wherein administering the microbiota restoration therapy composition to the patient with dysbiosis includes administering the microbiota restoration therapy via an enema tube.

### Claim 14 (depends on 11)

The method of claim 11, wherein administering the microbiota restoration therapy composition to the patient with dysbiosis includes administering the microbiota restoration therapy composition orally.

### Claim 15 (depends on 11)

The method claim 11, wherein the largest population of the bacteria included in the microbiota restoration therapy composition is from the family Bacteroidaceae.

### Claim 16 (depends on 11)

The method claim 11, wherein the largest population of the bacteria included in the microbiota restoration therapy composition is from the family Ruminococcaceae.

### Claim 17 (depends on 11)

The method of claim 11, wherein the largest population of the bacteria included in the microbiota restoration therapy composition is from the order Bacteroidales.

### Claim 18 (depends on 15)

The method of claim 15, wherein the second largest population of the bacteria included in the processed human fecal preparation is from the family Ruminococcaceae or Rikenellaceae.

### Claim 19 (depends on 18)

The method of claim 18, wherein the third largest population of the bacteria included in the processed human fecal preparation is from the family Ruminococcaceae, Rikenellaceae, Eubacteriaceae, Clostridiaceae, or Lachnospiraceae.

### Claim 20

A method for treating an imbalance of the intestinal bacterial flora, the method comprising:
administering a microbiota restoration therapy composition to a patient with an imbalance of the intestinal bacterial flora; and
wherein the microbiota restoration therapy composition comprises a mixture of an effective amount of fecal microbiota from a fresh human fecal sample and a mixture of polyethylene glycol and saline, the polyethylene glycol added to the fresh human stool sample at a concentration of 30-90 g/L.
